Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

The majority of patients may safely take glucagon-like peptide 1 receptor agonists (GLP-1 RAs) before elective surgery and ...

Wegovy manufacturer Ascendis Pharma has been tasked with supporting the development of a once-monthly GLP-1 drug.

The costs for 806 patients with overweight or obesity and heart failure were analyzed in one study. For those patients, the average total medical costs dropped from $29,654 before treatment began to ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

But patients taking GLP-1 drugs did have a greater likelihood of retained gastric contents and of aborted upper endoscopies, ...

In a practice-changing guideline reversal, medical societies advised on Tuesday that most patients do not need to stop taking ...

The FDA has updated the labels for all GLP-1 receptor agonists, including popular medications Ozempic, Wegovy, Saxenda and Mounjaro, to include a new warning about the risk of pulmonary aspiration ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) ...

Novo Nordisk's valuation remains high, trading at a significant historical premium. Click here to see why NVO stock is a Sell ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...